In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis’ Big Bet On A Diversified Hybrid Model

Executive Summary

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Advertisement

Related Content

How The Pfizer/Allegan Deal Got Done: Inside The Twists And Turns Of A Mega-Merger
Actavis Puts Greater Emphasis On Branded Rx By Taking Allergan Name
Pharma M&A Passed $200B In 2014, Primed For More In 2015
Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says
Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest
Forest’s Board Grows, As Icahn Gains Second Director’s Seat
Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …
Many New Products For Forest, But Not Enough To Fill The Lexapro Gap
Teva Swoops In To Snatch Cephalon For $6.7 Billion
Watson Acquires Arrow Group And Expands Its Global Footprint

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel